Journal of Shandong University (Health Sciences) ›› 2026, Vol. 64 ›› Issue (10): 60-70.doi: 10.6040/j.issn.1671-7554.0.2026.1323
SHANG Pan, CHENG Jie, GE Xiaoyan, WANG Yueyuan, YU Xiao
CLC Number:
| [1] Segerstolpe Å, Palasantza A, Eliasson P, et al. Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes[J]. Cell Metabolism, 2016, 24(4): 593-607. [2] Patel S N, Mathews C E, Chandler R, et al. The foundation for engineering a pancreatic islet niche[J]. Front Endocrinol(Lausanne), 2022, 13: 881525. DOI: 10.3389/fendo.2022.881525 [3] Huising M O. Paracrine regulation of insulin secretion[J]. Diabetologia, 2020, 63(10): 2057-2063. [4] Aldous N, Moin A S M, Abdelalim E M. Pancreatic beta-cell heterogeneity in adult human islets and stem cell-derived islets[J]. Cell Mol Life Sci, 2023, 80(6): 176. DOI: 10.1007/s00018-023-04815-7 [5] Bi H, Ye K, Jin S. Proteomic analysis of decellularized pancreatic matrix identifies collagen V as a critical regulator for islet organogenesis from human pluripotent stem cells[J]. Biomaterials, 2020, 233: 119673. DOI: 10.1016/j.biomaterials.2019.119673 [6] Cosentino C, Regazzi R. Crosstalk between macrophages and pancreatic beta-cells in islet development, homeostasis and disease[J]. Int J Mol Sci, 2021, 22(4).1765. DOI: 10.3390/ijms22041765 [7] Zakharov P N, Hu H, Wan X, et al. Single-cell RNA sequencing of murine islets shows high cellular complexity at all stages of autoimmune diabetes[J]. J Exp Med, 2020, 217(6).e20192362. DOI: 10.1084/jem.20192362 [8] van der Meulen T, Donaldson C J, Cáceres E, et al. Urocortin 3 mediates somatostatin-dependent negative feedback control of insulin secretion[J]. Nature Medicine, 2015, 21(7): 769-776. [9] Tong J C L, Frazer-Morris C, Shilleh A H, et al. Loca-lized GLP1 receptor pre-internalization directs pancreatic alpha cell to beta cell communication[J]. Cell Metab, 2025, 37(8): 1698-1714. [10] Pourhosseinzadeh M S, Huang J L, Shin D, et al. Heterogeneity in the coordination of delta cells with beta cells is driven by both paracrine signals and low-density Cx36 gap junctions[J]. Proc Natl Acad Sci U S A, 2025, 122(38): e2504151122. DOI: 10.1073/pnas.2504151122 [11] Weitz J R, Makhmutova M, Almaca J, et al. Mouse pancreatic islet macrophages use locally released ATP to monitor beta cell activity[J]. Diabetologia, 2018, 61(1): 182-192. [12] Sonoyama S, Mizokami A, Sano T, et al. Hyaluronan induces ERK activation with minimal transcriptomic changes in pancreatic alpha-cells[J]. Biochem Biophys Rep, 2026, 45: 102525. DOI: 10.1016/j.bbrep.2026.102525 [13] Rorsman P, Huising M O. The somatostatin-secreting pancreatic delta-cell in health and disease[J]. Nat Rev Endocrinol, 2018, 14(7): 404-414. [14] De Vos A, Heimberg H, Quartier E, et al. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression [J]. J Clin Invest, 1995, 96(5): 2489-2495. [15] Lai B K, Chae H, Gomez-Ruiz A, et al. Somatostatin is only partly required for the glucagonostatic effect of glucose but is necessary for the glucagonostatic effect of K(ATP)channel blockers [J]. Diabetes, 2018, 67(11): 2239-2253. [16] Xu S F S, Andersen D B, Izarzugaza J M G, et al. In the rat pancreas, somatostatin tonically inhibits glucagon secretion and is required for glucose-induced inhibition of glucagon secretion [J]. Acta Physiol(Oxf), 2020, 229(3): e13464. DOI: 10.1111/apha.13464 [17] Wang K Y, Gao M X, Qi H B, et al. Differential contributions of G protein- or arrestin subtype-mediated signalling underlie urocortin 3-induced somatostatin secretion in pancreatic delta cells [J]. Br J Pharmacol, 2024, 181(15): 2600-2621. [18] Ho K H, Barmaver S N, Gibson S E, et al. Paracrine hormonal signals from islet α-cells regulate microtubule dynamics in β-cells to promote insulin secretion in mouse and human islets [J]. Diabetes, 2026, 75(3): 494-505. [19] Rodriguez-Diaz R, Dando R, Jacques-Silva M C, et al. Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans [J]. Nat Med, 2011, 17(7): 888-892. [20] Armour S L, Frueh A, Chibalina M V, et al. Glucose controls glucagon secretion by regulating fatty acid oxidation in pancreatic alpha-cells [J]. Diabetes, 2023, 72(10): 1446-1459. [21] Svendsen B, Larsen O, Gabe M B N, et al. Insulin secretion depends on intra-islet glucagon signaling [J]. Cell Rep, 2018, 25(5): 1127-1134. [22] Grosjean A, Jalon A, Leveau C, et al. An islet-resident macrophage antioxidant program preserves beta cell physiology [J]. Sci Immunol, 2025, 10(113): eadz5181. DOI: 10.1126/sciimmunol.adz5181 [23] Chen X, Shao J, Brandenburger I, et al. FFAR4-mediated IL-6 release from islet macrophages promotes insulin secretion and is compromised in type-2 diabetes [J]. Nat Commun, 2025, 16(1): 3422. DOI: 10.1038/s41467-025-58706-5 [24] Thai L M, OReilly L, Reibe-Pal S, et al. Beta-cell function is regulated by metabolic and epigenetic programming of islet-associated macrophages, involving Axl, Mertk, and TGFbeta receptor signaling [J]. iScience, 2023, 26(4): 106477. DOI: 10.1016/j.isci.2023.106477 [25] Wang L K, Kong C C, Yu T Y, et al. Endoplasmic reticulum stress and forkhead box protein O1 inhibition mediate palmitic acid and high glucose-induced beta-cell dedifferentiation [J]. World J Diabetes, 2025, 16(5): 95431. DOI: 10.4239/wjd.v16.i5.95431 [26] Nguyen H T, Ly L D, Ngo T T T, et al. Palmitate impairs autophagic degradation via oxidative stress/perilysosomal Ca2+ overload/mTORC1 activation pathway in pancreatic beta cells [J]. JCI Insight, 2025, 10(24): e192827. DOI: 10.1172/jci.insight.192827 [27] Noguchi G M, Huising M O. Integrating the inputs that shape pancreatic islet hormone release [J]. Nat Metab, 2019, 1(12): 1189-1201. [28] Cheng J, Yang Z, Ge X Y, et al. Autonomous sensing of the insulin peptide by an olfactory G protein-coupled receptor modulates glucose metabolism [J]. Cell Metabolism, 2022, 34(2): 240-255. [29] Walker E M, Pearson G L, Lawlor N, et al. Retrograde mitochondrial signaling governs the identity and maturity of metabolic tissues [J]. Science, 2025, 388(6743): eadf2034. DOI: 10.1126/science.adf2034 [30] Sertbas M, Ulgen K O. Genome-scale metabolic mode-ling of human pancreas with focus on Type 2 diabetes [J]. OMICS, 2025, 29(4): 125-138. [31] Kristinsson H, Sargsyan E, Manell H, et al. Basal hypersecretion of glucagon and insulin from palmitate-exposed human islets depends on FFAR1 but not decreased somatostatin secretion [J]. Sci Rep, 2017, 7(1): 4657. DOI: 10.1038/s41598-017-04730-5 [32] Croze M L, Flisher M F, Guillaume A, et al. Free fatty acid receptor 4 inhibitory signaling in delta cells regulates islet hormone secretion in mice [J]. Mol Metab, 2021, 45: 101166. DOI: 10.1016/j.molmet.2021.101166 [33] Du Y Q, Sha X Y, Cheng J, et al. Endogenous lipid-GPR120 signaling modulates pancreatic islet homeostasis to different extents [J]. Diabetes, 2022, 71(7): 1454-1471. [34] Alén R, Garcia-Martinez I, Cobo-Vuilleumier N, et al. Effect of lipotoxic hepatocyte-derived extracellular vesicles in pancreas inflammation: essential role of macrophage TLR4 in beta cell functionality [J]. Diabetologia, 2025, 68(8): 1801-1822. [35] Wang J L, Dou X D, Cheng J, et al. Functional scree-ning and rational design of compounds targeting GPR132 to treat diabetes [J]. Nat Metab, 2023, 5(10): 1726-1746. [36] Frendi S, Chassac A, Veron K, et al. Protective role of oleic acid against palmitic acid-induced pancreatic fibrosis [J]. J Transl Med, 2025, 23(1): 416. DOI: 10.1186/s12967-025-06313-9 [37] Soultoukis G A, Leer M, Kehm R, et al. Pancreatic stellate cells have adipogenic and fibrogenic potentials but only show increased pro-fibrogenic propensity upon aging [J]. Redox Biology, 2025, 86: 103791. DOI: 10.1016/j.redox.2025.103791 [38] Litewka J J, Jakubowska M A, Targosz-Korecka M, et al. Biophysical and biochemical signatures of pancreatic stellate cell activation: insights into mechano-metabolic signalling from atomic force microscopy and Raman spectroscopy [J]. Cell Commun Signal, 2025, 23(1): 363. DOI: 10.1186/s12964-025-02354-1 [39] Qiu J, Zhu P, Shi X, et al. Identification of a pancreatic stellate cell gene signature and lncRNA interactions associated with type 2 diabetes progression [J]. Front Endocrinol(Lausanne), 2024, 15: 1532609. DOI: 10.3389/fendo.2024.1532609 [40] 中华医学会内分泌学分会, 中国医药生物技术协会慢病管理分会. 代谢功能障碍相关脂肪胰的诊断与治疗专家共识(2026版)[J]. 中华内分泌代谢杂志, 2026, 42(8): 704-718. [41] Hamada S, Matsumoto R, Masamune A. Pancreatic stellate cells and metabolic alteration: physiology and pathophysiology [J]. Front Physiol, 2022, 13: 865105. DOI: 10.3389/fphys.2022.865105 [42] 中华医学会糖尿病学分会. 中国糖尿病防治指南(2024版)[J]. 中华糖尿病杂志, 2025, 17(1): 16-139. [43] McGill J B, Hirsch I B, Parkin C G, et al. The current and future role of insulin therapy in the management of type 2 diabetes: a narrative review [J]. Diabetes Ther, 2024, 15(5): 1085-1098. [44] Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin [J]. Diabetes, 2002, 51(Suppl 1): 134-137. [45] Cordiner R L M, Bedair K, Mari A, et al. Low-dose sulfonylurea plus DPP-4 inhibitor lower blood glucose and enhance beta-cell function without hypoglycemia [J]. J Clin Endocrinol Metab, 2024, 109(8): 2106-2115. [46] de Bray A, Roberts A G, Armour S, et al. Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain [J]. Nat Metab, 2025, 7(8): 1536-1549. [47] Delgadillo Silva L F, Larouche S, Prat A, et al. 1814-P: impact of glucagon-like peptide 1 receptor(GLP-1R)agonism on β-Cell Ca2+ dynamics within the pancreatic islet in vivo [J]. Diabetes, 2025, 74(S1): 1814. DOI: 10.2337/db25-1814-P [48] Bianchi F, Roccabianca P, Vianello E, et al. Inhibition of DPP-4 attenuates endotoxemia-induced NLRC4 inflammasome and inflammation in visceral adipose tissue of mice fed a high-fat diet [J]. Biomolecules, 2025, 15(3): 333. DOI: 10.3390/biom15030333 [49] Feng Y, Shang B, Yang Y, et al. Impact of dpp-4 inhibitors on interleukin levels in type 2 diabetes mellitus [J]. J Clin Endocrinol Metab, 2025, 110(4): 1195-1204. [50] Chai S Y, Zhang R Y, Ning Z Y, et al. Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and beta-cell function in type 2 diabetes: a meta-analysis [J]. World J Diabetes, 2025, 16(7): 107335. DOI: 10.4239/wjd.v16.i7.107335 [51] Shimoda M, Katakura Y, Mashiko A, et al. Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic beta-cell function: randomized, parallel-group, multicenter, open-label study(SECRETE-I study)[J]. Front Endocrinol(Lausanne), 2024, 15: 1412553. DOI: 10.3389/fendo.2024.1412553 [52] Hirose T, Takagi H, Kuno M, et al. Dapagliflozin increased pancreatic beta cell proliferation and insulino-genic index in mice fed a high-fat and high-sodium chloride diet [J]. Biochem Biophys Res Commun, 2025, 749: 151364. DOI: 10.1016/j.bbrc.2025.151364 [53] Parsi P, Saharkhiz S, Farani M R, et al. Drug-induced regeneration of pancreatic beta cells: an approach to cellular therapeutic targets [J]. Cell Regen, 2025, 14(1): 39. DOI: 10.1186/s13619-025-00255-9 [54] Hong S W, Lee J, Cho J H, et al. Pioglitazone atte-nuates palmitate-induced inflammation and endoplasmic reticulum stress in pancreatic beta-cells [J]. Endocrinol Metab(Seoul), 2018, 33(1): 105-113. [55] Archana P, Durai Ananda Kumar T, Vijaya Ganesh N, et al. Decades old glitazones still find niche in drug discoveries as PPAR-gamma agonists: medicinal chemistry perspective, structure-activity relationships and therapeutic implications [J]. Bioorg Med Chem, 2025, 131: 118393. DOI: 10.1016/j.bmc.2025.118393 [56] El K, Douros J D, Willard F S, et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets [J]. Nat Metab, 2023, 5(6): 945-954. [57] Coskun T, Sloop K W, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept [J]. Mol Metab, 2018, 18: 3-14. DOI: 10.1016/j.molmet.2018.09.009 [58] Heise T, Mari A, DeVries J H, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial [J]. Lancet Diabetes Endocrinol, 2022, 10(6): 418-429. [59] Thomas M K, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes [J]. J Clin Endocrinol Metab, 2021, 106(2): 388-396. [60] Spezani R, Marinho T S, Macedo Cardoso L E, et al. Pancreatic islet remodeling in cotadutide-treated obese mice [J]. Life Sci, 2023, 327: 121858. DOI: 10.1016/j.lfs.2023.121858 [61] Visentin R, Schiavon M, Gobel B, et al. Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes [J]. Diabetes Obes Metab, 2020, 22(4): 640-647. [62] Ekinci E I, Maldonado S G, Unseld A, et al. Dual glucagon and GLP-1 receptor agonist survodutide improves biomarkers of beta-cell function and insulin sensitivity in people with type 2 diabetes or living with overweight/obesity [J]. Diabetes Obes Metab, 2026, 28(9): 8242-8253. [63] Bluher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA(1c)and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial [J]. Diabetologia, 2024, 67(3): 470-482. [64] Blossom V, Ullal S D, Rai R, et al. Repurposing the hypoglycaemic agents for neuroinflammation, a comprehensive review [J]. 3 Biotech, 2025, 15(9): 281. DOI: 10.1007/s13205-025-04455-7 [65] Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin [J]. J Clin Endocrinol Metab, 2004, 89(11): 5535-5541. [66] Bi Y, Tong G Y, Yang H J, et al. The beneficial effect of metformin on beta-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes [J]. Diabetes Metab Res Rev, 2013, 29(8): 664-672. [67] Gottmann P, Speckmann T, Stadion M, et al. Transcriptomic heterogeneity of non-beta islet cells is associated with type 2 diabetes development in mouse models [J]. Diabetologia, 2025, 68(1): 166-185. [68] Pagkali A, Makris A, Brofidi K, et al. Pathophysiological mechanisms and clinical associations of non-alcoholic fatty pancreas disease [J]. Diabetes Metab Syndr Obes, 2024, 17: 283-294. DOI: 10.2147/DMSO.S397643 |
| [1] | MA Xiaoli, LIN Hua, MENG Liying, ZUO Dan, LIU Shiqun, ZHANG Youtao, LIU Yuantao, SUN Jing, ZHANG Yuchao. Association of paired box 4 variants with risk of gestational diabetes mellitus, β-cell function, and perinatal outcomes [J]. Journal of Shandong University (Health Sciences), 2026, 64(8): 79-88. |
| [2] | LIN Hua, HUANG Qingxian, SUN Yanpei, LI Xuemei, SUN Jing, LIU Yuantao. Influencing factors and prediction model of Klebsiella pneumoniae infection in patients with pyogenic liver abscess [J]. Journal of Shandong University (Health Sciences), 2026, 64(6): 30-42. |
| [3] | JI Hanbing, WU Yutong, WU Sijia, HUANG Xin, LI Hongkai, CHEN Hao. Genetic evidence on the association of metformin targets with risk of fetal congenital nervous system malformations [J]. Journal of Shandong University (Health Sciences), 2026, 64(6): 86-93. |
| [4] | LI Xiping, QIU Mei, HUANG Ruifeng, LIN Huihui, LIU Sisi, LUO Hongying, WANG Yuyue, WANG Min, YANG Xiaotong. Research progress on the mechanism of berberines anti-atherosclerosis effects based on the synergistic effect of lipid deposition inhibition and metabolic clearance [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 77-83. |
| [5] | MENG Xiaomei, HAO Yaping, WANG Liang, YU Xiao, TANG Yuxiao. Correlation between the levels of serum Isthmin1, Gremlin2 and retinopathy in type 2 diabetic patients [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 102-107. |
| [6] | WANG Mengxing, XUE Fuzhong, YANG Fan. Blood glucose concentration prediction method for type 1 diabetes mellitus based on multi-modal cross-attention mechanism fusion [J]. Journal of Shandong University (Health Sciences), 2025, 63(8): 41-50. |
| [7] | SHEN Lujia, LU Tianwei, GONG Weiming, ZHAO Yansong, WANG Shukang, YUAN Zhongshang. Application of metabolomic risk score in predicting cardiovascular outcomes in patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2025, 63(8): 69-78. |
| [8] | CHEN Yingying, WANG Lu, HU Xifeng, ZHU Gaopei, XUE Fuzhong. A Bayesian network-based risk prediction study of stroke in patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2025, 63(8): 94-102. |
| [9] | CHEN Xujun, HE Guowei. Focus on further more use of arterial grafts in coronary artery bypass grafting in patients with coronary heart disease in China [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 1-5. |
| [10] | LU Shengxun, XING Yachuang, LUO Junhui, LIU Jie, HE Houle, WANG Zhiqiang, ZHANG Na. Diabetic patients arterial grafts in coronary artery bypass grafting: current research status [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 33-39. |
| [11] | LIN Xiaoqian, FENG Maoyan, MOU Zheng. Pharmaceutical characteristics and clinical utility of dipeptidyl peptidase-4 inhibitors [J]. Journal of Shandong University (Health Sciences), 2024, 62(12): 43-48. |
| [12] | LI Jinquan, GAO Meifang, YAN Fei, DONG Ming. Frequency and risk factors of muscle cramp in 136 cases of type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 20-24. |
| [13] | LU Xingchen, QIANG Ye, LIU Xinyu, ZUO Dan, JIANG Zihan, ZHANG Yuchao, LIU Yuantao, MA Xiaoli. Effects of NR4A1 on thapsigargin-induced glucose metabolism dysfunction in C2C12 myotube cells [J]. Journal of Shandong University (Health Sciences), 2023, 61(11): 38-47. |
| [14] | HAN Mei, MENG Weijing, TAO Zikun, YANG Xi, XU Yaqi, MU Huaxia, BU Weixiao, WANG Suzhen, SHI Fuyan. Causal mediation analysis with multiple-mediator of hypertension and depression between type 2 diabetes mellitus and cognitive function based on G-computation [J]. Journal of Shandong University (Health Sciences), 2023, 61(10): 101-108. |
| [15] | LI Tao, YANG Chunlin, DU Tong, LI Heng, WANG Congcong, LI Xiaoli, DUAN Ruisheng,ZHANG Peng. Effects of diabetes mellitus on the subsets and function of NK cells in myasthenia gravis [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 31-36. |
|
||
